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Chromosome 11q13.5 variant associated with childhood
eczema: An effect supplementary to filaggrin mutations
Gra´inne M. O’Regan, MB,a Linda E. Campbell, BSc,b Heather J. Cordell, DPhil,c Alan D. Irvine, MD,a,d W. H. Irwin McLean,
DSc, FRSE, FMedSci,b and Sara J. Brown, MDa,b Dublin, Ireland, and Dundee and Newcastle Upon Tyne, United KingdomBackground: Atopic eczema is a common inflammatory skin
disease with multifactorial etiology. The genetic basis is
incompletely understood; however, loss of function mutations in
the filaggrin gene (FLG) are the most significant and widely
replicated genetic risk factor reported to date. The first genome-
wide association study in atopic eczema recently identified 2
novel genetic variants in association with eczema susceptibility:
a single nucleotide polymorphism on chromosome 11q13.5
(rs7927894) and a single nucleotide polymorphism (rs877776)
within the gene encoding hornerin on chromosome 1q21.
Objective: To test the association of these 2 novel variants with
pediatric eczema and to investigate their interaction with FLG
null mutations.
Methods: Case-control study to investigate the association of
rs7927894, rs877776 and the 4 most prevalent FLG null
mutations with moderate-severe eczema in 511 Irish pediatric
cases and 1000 Irish controls. Comprehensive testing for
interaction between each of the loci was also performed.
Results: The association between rs7927894 and atopic eczema
was replicated in this population (P 5 .0025, x2 test; odds ratio,
1.27; 95% CI, 1.09-1.49). The 4 most common FLG null variants
were strongly associated with atopic eczema (P 5 1.26 3 10250;
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.rs7927894 association was independent of the well-established
FLG risk alleles and may be multiplicative in its effect. There
was no significant association between rs877776 and pediatric
eczema in this study.
Conclusion: Single nucleotide polymorphism rs7927894 appears
to mark a genuine eczema susceptibility locus that will require
further elucidation through fine mapping and functional
analysis. (J Allergy Clin Immunol 2010;125:170-4.)
Key words: Allergy, atopic dermatitis, atopy, inflammatory skin dis-
ease, skin barrier
Atopic eczema1 is a common inflammatory skin disease result-
ing in considerable morbidity in severely affected children.2 Ge-
netic and environmental factors each contribute significantly to
the etiopathogenesis of this disease, but our understanding of
the role of genetic variation in atopic eczema remains limited, de-
spite considerable research effort.3
An important breakthrough in understanding occurred with the
identification of null mutations in the gene encoding filaggrin
(FLG) on chromosome 1q21 as a major risk factor for atopic ec-
zema.4 This insight has also served to focus attention on the role
of epidermal barrier dysfunction as a keymechanism (perhaps the
primary event) in eczema pathogenesis.5 FLG remains the most
highly significant and widely replicated genetic risk factor for
atopic eczema, with an estimated odds ratio (OR) of 3.12.6 How-
ever, even in the most severe case series, a maximum of 50% of
cases carry FLG null alleles.7
The first genome-wide association study in atopic eczema has
recently identified a novel susceptibility variant: a single nucle-
otide polymorphism (SNP) on chromosome 11q13.5.8 The same
study reported an additional susceptibility SNP located within the
hornerin gene (HRNR), which encodes the protein hornerin, on
chromosome 1q21, as well as again confirming the association
of 4 prevalent FLG null mutations with atopic eczema in a Euro-
pean population.8
We aimed to investigate the roles of these 2 novel risk
variants and their interactions with the well described FLG null
mutations in a collection of Irish children with moderate-to-se-
vere eczema.1METHODS
Study participants
A total of 511 unrelated children of self-reported Irish ancestry with
moderate-to-severe eczema were recruited from tertiary referral pediatric
dermatology clinics based at 1 center (Our Lady’s Children’s Hospital,
Dublin). The diagnosis of eczema was made by experienced dermatologists
according to the United Kingdom diagnostic criteria9 with disease severity
scored according to the Nottingham Eczema Severity Score.10
A total of 1000 unselected control samples were obtained from the
previously described population-based Trinity Biobank Control samples.11
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O’REGAN ET AL 171Abbreviations usedAIC: Akaike information criterionBIC: Bayesian information criterionFLG: Filaggrin geneHRNR: Hornerin geneOR: Odds ratioSNP: Single nucleotide polymorphismDemographic and clinical data relating to the 511 Irish eczema cases and
the 1000 individuals from the Irish control population are presented in Tables I
and II.
The study was carried out in accordance with the Declaration of Helsinki
Principles and approved by the Research Ethics Committee of Our Lady’s
Children’s Hospital Crumlin (cases) and Trinity College Dublin (Trinity
Biobank Control samples). All subjects or the subjects’ guardians gavewritten
informed consent.Genotyping methods
The 11q13.5 SNP (rs7927894) and the HRNR SNP (rs877776) were typed
by the available predesigned Taqman allelic discrimination assays (Applied
Biosystems, Foster City, Calif) according to the manufacturer’s recommended
protocols.
The 4 filaggrin loss-of-function variants that are most common in the
Irish population (R501X, 2282del4, R2447X, and S3247X) were largely
genotyped by using Taqman allelic discrimination assays, as described
previously,12 or with modified and simplified protocols (Campbell and
McLean, July 2009).Statistical genetic analysis
Allele and genotype frequencies were compared by using the x2 test, the
Fisher exact test, and logistic regression analysis, performed with the statisti-
cal analysis package STATA (StataCorp LP, College Station, Tex). Logistic re-
gression models the log odds of disease as a linear function of variables
encoding allele or genotype effects at the relevant locus or loci. For the allele
model, a genotype variable coded as 0, 1, or 2 (according to the number of mu-
tant alleles carried at a locus) was included in the regression equation. For the
genotype model, a variable coding for homozygosity with respect to the mu-
tant alleles was also included in the regression equation.
Tests for interaction were performed by including the main effects of
rs7927894 and the relevant FLG mutation together with their interaction var-
iables in the logistic regression equation.13 Because very few homozygous
FLG mutant individuals were observed, we considered only a single main ef-
fect of FLG heterozygosity together with either a genotype effect at rs7927894
(resulting in 2 interactionvariables, ie, a 2-df interaction test) or an allele effect
at rs7927894 (resulting in a single interaction variable, ie, a 1-df interaction
test).
The fit of different models to the data was compared via a Wald test (which
assesses the significance of dropping a particular term from a regression
model) and via calculation of the Akaike information criterion (AIC) and
Bayesian information criterion (BIC). These 2 criteria measure the goodness
of fit of an estimated statistical model in light of the number of observations
and the number of estimated parameters. When using the AIC (or BIC) to
compare models that have been fitted to an identical set of observations, the
preferred model is the one with the lowest AIC (or BIC) value.Power calculation
Using the program QUANTO14 and assuming a population prevalence of
15%, we estimated that our sample had 71% power to detect the previously
reported 11q13.5 (rs7927894) effect (OR, 1.22; allele frequency, 0.363) at
2-sided P value .05 (1-sided P value, .025). Our sample had only 43% power
to detect the previously reportedHRNR (rs877776) effect (maximumOR, 1.2;allele frequency, 0.158).We had>70% power to detect an interaction effect of
OR of 1.64 or above between the 11q13.5 SNP (rs7927894) and FLG assum-
ing a combined FLG mutation frequency of 0.078 and a FLG OR of 3 (at the
lower end of data from comparable studies published previously).15RESULTS
Replication of the 11q13.5 locus association but not
the HRNR association
Genotyping results for the 11q13.5 SNP (rs7927894), the
HRNR SNP (rs877776), and the 4 FLG null mutations, R501X,
2282del4, S3247X, and R2447X,12,16 are shown in Table III, in
addition to their corresponding allele frequencies. The FLG null
mutations each showed strong and significant association with
pediatric eczema in this case/control study when analyzed indi-
vidually and as a combined null genotype (Fisher exact test, P
5 1.26 3 10250). The rs7927894 SNP also showed a significant
association with eczema (x2 test, P 5 .0025), but the rs877776
SNP was not significant (x2 test, P 5 .318).
The results of logistic regression analyses to investigate the OR
of disease are shown in Table IV. Separate analyses performed us-
ing allele-based and genotype models demonstrated the overall
OR when allele frequencies were compared between case and
control groups (allele model) and the distinct ORs relating to
the heterozygotes and homozygotes for each genetic variant and
the combined FLG null genotype (genotype model).
Tests comparing the fit of the genotype versus the allele
models are shown in this article’s Table E1 in the Online Repos-
itory at www.jacionline.org. The OR associated with the
rs7927894 SNP was estimated at 1.27 by using the allele model;
the genotype model gave an OR of 1.27 for heterozygote individ-
uals and 1.63 for homozygotes (Table IV). The genotype model
did not fit significantly better than the allele model (P 5 .95; the
allele model had lower AIC and BIC). In comparison, the com-
bined FLG null genotype showed an OR of 5.81 (95% CI, 4.51-
7.49) by using the allele model, 5.23 (95% CI, 3.96-6.91) for het-
erozygotes and 140 (95% CI, 19.18-1021) for homozygotes, in
keeping with semidominant inheritance. However, the low num-
ber of homozygous individuals meant that the difference be-
tween the genotype and allele models was not statistically
significant (P 5 .12), although the genotype model did give
the lower AIC, suggesting that it might be preferred over the al-
lele model.The 11q13.5 and FLG loci are independent and
multiplicative
Additional analyses performed to test the statistical signifi-
cance of the rs7927894 SNP having controlled for the presence/
absence of the strongly significant FLG null genotype indicated
that rs7927894 still shows a statistically significant effect (P 5
.0025) with an OR of 1.22 (95% CI, 1.02-1.26). A mathematical
model combining the effects of rs7927894 andFLG null genotype
in a linear model fits the data significantly better (P5 .0258) than
allowing for FLG alone. Furthermore, tests for interaction
between each of the FLG and rs7927894 risk alleles (Table E1,
results based on the cross-classification of genotypes shown
in this article’s Table E2 in the Online Repository at www.jacion
line.org) showed no evidence of statistically significant epistatic
effects on the basis of either Wald tests from logistic regression
or comparison of AIC and BIC values. Hence these data
TABLE II. Characterization of Irish control population
Male sex, n (%) 296/1000 (29.6)
Age (y), mean (SD) 33.34 (15.54)
Mean age range in years, n (%)
<25 y 212 (21.2)
25-50 y 620 (62.0)
>50 y 158 (15.8)
The control population represents 1000 consecutive Trinity Biobank Control samples,
derived from Irish adult blood donors.
TABLE I. Characterization of 511 Irish pediatric eczema cases
Male sex, n (%) 315/ 511 (61.6)
Age (y), mean (SD) 4.17 (3.96)
No. in age group (%)
<2 y 201 (39.3)
2-5 y 141 (27.6)
5-10 y 104 (20.4)
10-15 y 55 (10.8)
>15 y 10 (2.0)
Nottingham Eczema Severity Score, mean (SD) 11.29 (4.60)
No. of cases with coexistent asthma (%) 132/511 (25.8)
Serum IgE level (kU/L), mean (SD) 2130.56 (5510.41)
Nottingham Eczema Severity Score, range, 0 to 15, where 9 to 11 defines moderate
and 12 to 15 severe disease.10
J ALLERGY CLIN IMMUNOL
JANUARY 2010
172 O’REGAN ET ALdemonstrate that the risk of disease in individuals having FLG
null mutations and risk alleles at rs7927894 is well fitted by amul-
tiplicative model, with the OR multiplied by 5.21 for possession
of a single FLG null allele (or 138 for possession of 2 FLG null
alleles, although note the wide associated CI [18.92-1009.42])
and 1.22 times for each rs7927894 mutation (therefore 5.21 3
1.223 1.225 7.75 for an individual with a single FLG null allele
and homozygous for mutations in rs7927894).DISCUSSION
Many candidate gene studies in atopic eczema have been
performed on relatively small case collections and have generated
data that have not been replicated in further studies.17,18 However,
in 1 of 5 reported microsatellite-based genome screens, the 1q21
locus was identified, andwe have shown that a large component of
this signal was a result of FLG null mutations.4 No additional loci
have been identified with any certainty by other screening studies,
and therefore the recent genome-wide association study, per-
formed on German, French, and East European cases,8 was a
very welcome addition to the field. As well as confirming the
1q21 locus and the hegemony of FLG mutations, this study gen-
erated other loci worthy of further investigation, of which 2 have
been investigated in the current case-control study.
One SNP, rs877776, is located within HRNR,8 a gene encoding
hornerin, anS100 fused-typeprotein thatmaybe involved inepider-
mal barrier formation.19 BothHRNR andFLG liewithin the epider-
mal differentiation complex, a dense cluster of genes on
chromosome1q21,many ofwhich are thought to be involved in ep-
ithelial barrier function.20 Our 511 pediatric eczema cases include
the discovery cohort forFLG loss-of-functionmutations4,16 and are
verywell characterized for the prevalent and rareFLG null variants.
In the current study, we could not replicate the HRNR association.
However, this may simply be because our study is underpowered
to detect this effect given its relatively low allele frequency andeffect size. An alternative explanation is that the HRNR effect
may be limited to the German/French/East European populations,
or at least that it is not important in the Irish population. It is also
possible that this SNP is in linkage disequilibrium with an as yet
unidentified FLG null mutation in the study populations used for
the genome-wide association study. Given that FLG mutations
are highly population-specific,21 this seems a likely explanation.
However, high-density SNP mapping, detailed sequencing of
FLG, and examination of haplotypes in each of these populations
would be required to confirm or refute this hypothesis.
The second novel SNP, rs7927894, is located on chromosome
11q13.5. We have confirmed an association of rs7927894 with
eczema in a large, well phenotyped case collection of children
with moderate-to-severe eczema. This case series represents a
different population of white European ancestry than the discov-
ery case series,8 as discussed in the previous paragraph. However,
the ORs we obtained were very similar to the discovery cohort:
the homozygous carriers of the risk allele show an OR of 1.63
(95% CI, 1.18-2.24) in the Irish pediatric eczema cases compared
with an OR of 1.47 (95% CI, 1.29-1.68) in the European adult
cases,8 providing replication evidence for this genetic association.
Furthermore, the frequency of the rs7927894 risk allele is similar
in our Irish population control group to that reported by Esparza-
Gordillo et al8; 14.5% of the Irish controls were homozygotes,
compared with approximately 13% in the European control pop-
ulation. The combination of such a prevalent risk allelewith, it ap-
pears, a substantial OR illustrates the potential importance of this
novel susceptibility locus in eczema.
The gene or gene product affected by the rs7927894 risk allele
defined by this anonymous SNP remains to be identified and
functionally characterized; rs7927894 lies in an intergenic region
between 2 annotated genes, chromosome 11 open reading frame
30 (C11orf30) and leucine rich repeat containing 32 (LRRC32)
(UCSC Genome Browser, Human Genome March 2006 assem-
bly, http://genome.ucsc.edu). C11orf30 encodes the EMSY pro-
tein, which has been shown to bind the BRCA2 breast cancer
susceptibility protein22 and may therefore play a role in epithelial
differentiation. The second nearby gene, LRRC32 (also known as
glycoprotein A repetitions predominant (GARP), has recently
been shown to be a cell surface molecule expressed on regulatory
T cells,23 and may therefore be a more likely candidate for atopic
eczema susceptibility, given the important role of T-cell–medi-
ated inflammation in atopic eczema.24 Although rs7927894 is
located in the same haplotype block as C11orf30,8 providing
tentative genetic evidence that this is the causative gene, it is
possible that nearby genes such as LRRC32 may be regulated
by sequences within this haplotype block. However, it is also pos-
sible that this SNP, or more likely, causative variants in linkage
disequilibrium with it, may be involved in long-range control of
more distant genes, well removed from either C11orf30 or
LRRC32. Defects in noncoding long-range control elements, in
many cases acting over distances spanning many intervening
genes, are an emerging disease mechanism.25 Finally, it should
be noted that there are some expressed sequence tag clusters close
to rs7927894 (UCSC Genome Browser) that may represent
further uncharacterized candidate genes.
Intriguingly, rs7927894 has also been identified as a suscep-
tibility factor for Crohn disease.8 Thus, beyond skin-specific
physical barrier genes, genes having an effect on susceptibility
to epithelial inflammation may have similar functions in diverse
inflammatory diseases affecting both skin and the gastrointestinal
TABLE III. Genotyping of the 11q13.5 SNP (rs7927894), the HRNR SNP (rs877776), and the 4 most prevalent FLG null mutations in 511
Irish eczema cases and 1000 individuals from an unselected Irish control population
rs7927894
(chr 11q13.5)
rs877776
(HRNR) R501X 2282del4 R2447X S3247X
Combined FLG null
genotype
Genotype Controls
Eczema
cases Controls
Eczema
cases Controls
Eczema
cases Controls
Eczema
cases Controls
Eczema
cases Controls
Eczema
cases Controls
Eczema
cases
AA 349 146 688 356 956 385 957 404 992 478 985 472 890 267
Aa 502 266 276 138 44 109 42 96 8 19 13 25 107 168
aa 144 98 26 7 0 2 0 6 0 0 1 2 1 42
Total 995 510 990 501 1000 496 999 506 1000 497 999 499 998 477
Minor allele
frequency (%)
39.7 45.3 16.6 15.2 2.2 11.4 2.1 10.7 0.4 1.9 0.8 2.9 5.5 26.4
x2 test from
logistic
regression
(allele model)
P 5 .0025 P 5 .318 P 5 2.13 3 10222 P 5 1.53 3 10219 P 5 1.75 3 1024 P 5 6.55 3 1025 P 5 5.25 3 10242
Fisher
exact test
(genotype
model)
P 5 .010 P 5 .309 P 5 6.07 3 10225 P 5 4.90 3 10222 P 5 9.14 3 1025 P 5 2.23 3 1025 P 5 1.26 3 10250
AA, Wild-type homozygous individuals for each genetic variant; Aa, wild-type/mutant heterozygous individuals; aa, individuals who are homozygous for each of the genetic
variants tested.
Each of the 2 SNPs and 3 of the 4 FLG mutations were in Hardy-Weinberg equilibrium within the control population; S3247X was significantly out of Hardy-Weinberg equilibrium
in the control group (P 5 .0001).
TABLE IV. Results of logistic regression analysis to estimate ORs for eczema by using allele and genotype models
rs7927894
(chr 11q13.5)
rs877776
(HRNR) R501X 2282del4 R2447X S3247X
Combined FLG null
genotype
OR calculated
using the allele
model
(95% CI)
1.27
(1.09-1.49)
0.90
(0.73-1.11)
6.20
(4.30-8.96)
5.58
(3.85-8.11)
4.93
(2.14-11.34)
3.52
(1.90-6.52)
5.81
(4.51-7.49)
OR calculated
using the genotype
model
(95% CI)
Heterozygotes
vs wild type
1.27
(0.99-1.61)
0.97
(0.76-1.23)
6.15
(4.25-8.90)
5.41
(3.70-7.92)
4.93
(2.14-11.34)
4.01
(2.03-7.91)
5.23
(3.96-6.91)
Homozygotes
vs wild type
1.63
(1.18-2.24)
0.52
(0.22-1.21)
NA NA NA 4.17
(0.38-46.14)
140
(19.18-1021)
NA, Not analyzed because of absence of homozygote individuals in the cases and/or control group.
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alence of atopic eczema in children with inflammatory bowel dis-
ease, and this cannot be explained by a differential prevalence of
FLG null mutations.26 Although currently highly speculative, it is
tempting to suggest that the 11q13.5 gene may contribute to a
TH1-dominant immune profile as seen in Crohn disease and
chronic atopic eczema lesions rather than the TH2-dominant le-
sions of acute atopic eczema.24
In conclusion, although we have replicated the association of
rs7927894 with eczema, much further work remains in identify-
ing the causative variant or variants at this locus as well as
functional analyses to determine how these sequence changes
contribute to the pathogenesis of this complex disease.We are grateful to our patients and their families for their participation in
this study. We thank Dr JoeMcPartlin, Trinity DNABiobank, Trinity College,
Dublin, for his assistance with the control samples and dataset.Key messages
d This replication of a novel variant on chromosome
11q13.5 (rs7927894), carried out in a large, carefully phe-
notyped collection of pediatric eczema cases, confirms the
locus to be of importance.
d The rs7927894 SNP is prevalent in the general population,
with a homozygote frequency of 14.5%; these individuals
have an estimated OR of 1.63 (95% CI, 1.18-2.24).
d The rs7927894 SNP has an effect that is independent of,
and supplementary to, the well established FLG null
mutations.
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TABLE E1. Results of statistical testing to compare the fit of genotype and allele models of disease
Model df
No. of
observations AIC BIC Nested model [AIC, BIC]
P value from Wald test from
logistic regression comparing
model with nested model
rs7927894 (genotype) 3 1505 1924.11 1940.06 rs7927894 (allele) [1922.12,
1932.75]
.95
rs7927894 (allele) 2 1505 1922.12 1932.75
rs87776 (genotype) 3 1491 1906.99 1922.92 rs87776 (allele) [1906.59,
1917.20]
.22
rs87776 (allele) 2 1491 1906.59 1917.20
R501X (allele) 2 1496 1795.79 1806.42
2282del4 (allele) 2 1505 1829.93 1840.56
R2447X (allele) 2 1497 1891.09 1901.71
S3247X (genotype) 3 1498 1893.92 1908.86 S3247X (allele) [1892.75,
1903.37]
.34
S3247X (allele) 2 1498 1892.75 1903.37
Combined FLG (genotype) 3 1475 1633.12 1649.01 Combined FLG (allele) [1635.00,
1645.59]
.12
Combined FLG (allele) 2 1475 1635.00 1645.59
rs7927894 (genotype) 1 R501X
(heterozygote)
1 2df interaction
6 1488 1789.70 1821.53 rs7927894 (genotype) 1 R501X
(het)
[1787.97, 1809.19]
.31
rs7927894 (allele) 1 R501X
(het)
1 1df interaction
4 1488 1787.46 1808.68 rs7927894 (allele) 1 R501X
(het)
[1785.99, 1801.90]
.47
rs7927894 (genotype) 1
2282del4 (het) 1 2df
interaction
6 1493 1823.15 1855.00 rs7927894 (genotype) 1
2282del4 (het)
[1819.17, 1840.41]
.99
rs7927894 (allele) 1 2282del4
(het)
1 1df interaction
4 1493 1819.15 1840.39 rs7927894 (allele) 1 2282del4
(het)
[1817.17, 1833.10]
.88
rs7927894 (allele) 1 R2447X
(het)
1 1df interaction
4 1491 1880.40 1901.63 rs7927894 (allele) 1 R2447X
(het)
[1878.64, 1894.56]
.63
rs7927894 (genotype) 1 S3247X
(het)
1 2df interaction
6 1490 1882.11 1913.94 rs7927894 (genotype) 1 S3247X
(het)
[1878.70, 1899.92]
.74
rs7927894 (allele) 1 S3247X
(het)
1 1df interaction
4 1490 1878.68 1899.91 rs7927894 (allele) 1 S3247X
(het)
rs7927894 (genotype) 1 FLG
(het)
1 2df interaction
6 1427 1619.32 1650.90 rs7927894 (genotype) 1 FLG
(het)
[1615.92, 1636.97]
.74
rs7927894 (allele) 1 FLG (het)
1 1df interaction
4 1427 1615.84 1636.89 rs7927894 (allele) 1 FLG (het)
[1613.97, 1629.76]
.71
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TABLE E2. Cross-classification of genotypes used for the interaction analysis
Controls Cases
rs7927894 rs7927894
AA Aa aa AA Aa aa
R501X AA 335 482 134 114 198 72
Aa 14 20 10 28 62 19
aa 0 0 0 0 1 1
2282del4 AA 335 479 138 116 210 77
Aa 14 22 6 27 52 17
aa 0 0 0 2 2 2
R2447X AA 346 497 144 138 248 91
Aa 3 5 0 6 10 3
aa 0 0 0 0 0 0
S3247X AA 343 496 142 136 245 90
Aa 5 6 2 7 15 3
aa 1 0 0 0 0 2
Combined FLG null genotype AA 312 448 126 79 138 49
Aa 36 53 18 47 92 29
aa 1 0 0 11 21 10
AA, Wild-type homozygous individuals for each genetic variant; Aa, wild-type/mutant heterozygous individuals; aa, individuals who are homozygous for each of the genetic
variants tested.
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